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Sir, 
Comments on ‘Treatment patterns of ranibizumab intravitreal injection and 
dexamethasone implant for retinal vein occlusion in the USA’ 
 
We commend a study comparing ophthalmology clinic visit frequency for 
patients receiving ranibizumab and dexamethasone for RVO (1). They make 
the case that visit burden for both treatments may not be significantly 
different, but highlight the importance of real world studies from countries 
other than the USA. We performed an audit of all patients who received 
intravitreal treatment with one drug type only for newly diagnosed RVO 
attending one clinic in the UK during one year. This was in 2014, and findings 
reflect a surge of referrals then given recent licensing of ranibizumab for 
RVOs in the UK. Fifty-six patients were identified, mean age 74y (range 30-
89) with 50% having a BRVO and 50% with a CRVO. Ranibizumab was given 
to 55% (n=31) and dexamethasone to 29% (n=16). There was no significant 
difference (p=0.7) in the follow-up periods for patients who received 
ranibizumab (mean 171.2 days, s.d. 46.3) compared to dexamethasone 
(mean 177.9 days, s.d. 64.8). The number of injections was significantly 
different for the two drugs (p<0.001), with a mean of 3.1 (s.d. 0.9) for 
ranibizumab and 1.1 (s.d. 0.3) for dexamethasone. For ranibizumab 55% 
received 3 injections and 29% received 4 injections, while for dexamethasone 
88% (n=14) received one injection. There was no significant difference 
(p=0.9) in BCVA from the first injection to follow-up: mean +7.3 letters (s.d. 
12.3) for ranibizumab and +7.8 letters (s.d. 8.6) for dexamethasone. Similarly 
central retinal thickness changes were not significantly different (p=0.95): -
165.5μm (s.d. 218.7) for ranibizumab, and -169.1μm (s.d. 152.3) for 
dexamethasone. IOP lowering topical treatment was needed in 5% following 
ranibizumab and 23% following dexamethasone. 
The visual results obtained fall short of those achieved in clinical trials and 
treatment patterns in our clinic are now closer to the label recommendations.  
Our practice was and remains to monitor patients on ranibizumab monthly, 
injecting if appropriate, and for dexamethasone to review patients 6 weeks 
following the implant, and then at least 3 months later depending on any prior 
clinical responses. Thus similar outcomes are obtainable with ranibizumab 
and dexamethasone but with far fewer treatment and non-treatment visits for 
the latter. 
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